| Document |
Document Title |
|
WO/2009/067600A2 |
The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory di...
|
|
WO/2009/067621A1 |
The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory di...
|
|
WO/2009/061652A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating ...
|
|
WO/2009/052288A1 |
The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable composit...
|
|
WO/2009/049180A2 |
The present invention relates to compounds of formula I'' useful as inhibitors of voltage -gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods ...
|
|
WO/2009/040507A1 |
Compounds of formula (IA) or (IB) have antibacterial activity : wherein W is =C(H)- or =N-; R3 is a radical of formula -(Alk1)m-(Z1)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z...
|
|
WO/2009/037485A1 |
Compounds of formula (IA) or (IB) have antibacterial activity: wherein W is =CH- or =N-; Ri and R2 are independently selected from hydrogen, fluoro and chloro, provided that Ri and R2 are not each hydrogen when W is =CH-; n is 0 or 1; X ...
|
|
WO/2009/034396A2 |
Methods for overcoming multiple herbicide resistance (MHR) in plants using inhibitors of GST suppression of Formula (I), novel chemical inhibitors of Formula (Ia), compositions comprising compounds of Formula (I), and uses and methods re...
|
|
WO/2009/030750A1 |
The present invention relates to compounds of Formula (I): as well as the cosmetic and pharmaceutical compositions containing such a compound.
|
|
WO/2009/025246A1 |
Disclosed are a method for producing an ammonium salt a fluorinated bis-sulfonylimide and a method for producing a lithium salt of a fluorinated bis-sulfonylimide, each by employing a practical and efficient method having a high collecti...
|
|
WO/2009/019445A1 |
There is provided a compound of formula (I): wherein Y has the meaning given in the description. Such compounds are potentially useful in the treatment of disorders or conditions caused by, linked to, or contributed to by, excess adiposi...
|
|
WO/2009/019446A1 |
There is provided the following compound of formula (I): which compound is of potential use in the treatment of cancer, such as breast cancer.
|
|
WO/2009/010429A2 |
The invention is concerned with novel heterocyclyl compounds of formula (I), wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts there...
|
|
WO/2009/011871A2 |
The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also...
|
|
WO/2009/012283A1 |
Compounds of formula I active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (I) wherein Ar is optionally substi...
|
|
WO/2009/008748A1 |
Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
|
|
WO/2008/157407A2 |
Compounds of formula (I) hat are inhibitors of transcription factors of leukemia cell lines are provided. In addition, pharmaceutical compositions including the inhibiting compounds and methods for treating leukemia are also provided.
|
|
WO/2008/151513A1 |
The invention provides a suspension concentrate of Zn Thiodiazole and preparation thereof. The suspension concentrate comprises Zn Thiodiazole 5-60%, wetting agent 2-8%, dispersant 2-5%, thickening agent 0-3%, antifreezing agent 0-5%, pr...
|
|
WO/2008/148744A1 |
Novel compounds that are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibit...
|
|
WO/2008/144500A2 |
The invention is directed to l-methyl-benzo[l,2,4]thiadiazine 1 -oxide derivatives and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
|
|
WO/2008/139845A1 |
Disclosed is an amide derivative having an excellent SCD inhibitory activity or a pharmacologically acceptable salt thereof. Specifically disclosed is an amide derivative represented by the general formula (I) below, or a pharmacological...
|
|
WO/2008/136382A1 |
Disclosed is a compound represented by the following formula: (wherein R1 presents an optionally substituted hydrocarbon group, an optionally substituted amino group, an optionally substituted hydroxy group or an optionally substituted h...
|
|
WO/2008/128639A1 |
The present invention relates to thiadiazolyl oxyphenyl amidines of the general formula (I), a method for the production thereof, the use of the amidines according to the invention for the control of undesired microorganisms, and an agen...
|
|
WO/2008/129129A1 |
Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein R is a heterocyclic or heterocyclic carbonyl moiety and R' is a group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted hetero...
|
|
WO/2008/128072A2 |
Axl kinase inhibitory compounds are disclosed, as well as compositions and methods of using the same in the treatment of cancer and other conditions mediated by and/or associated with Axl kinase.
|
|
WO/2008/123469A1 |
Disclosed is a compound having excellent SCD1 activity inhibitory action. Specifically disclosed is a compound represented by the general formula [B-0'] below, a pharmaceutically acceptable salt thereof, or a solvate thereof. [B-0'] (In ...
|
|
WO/2008/120093A1 |
The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I), as defined in the specification. The invention is also directed to compositions con...
|
|
WO/2008/116302A1 |
The present invention relates to novel compounds of the formula (I), wherein R'-R7, X, Y, D and n are as defined in the specification. These compounds are cysteine protease inhibitors which include but are not limited to inhibitors of ca...
|
|
WO/2008/111588A1 |
Disclosed is a method for efficiently producing difluoromethanebis(sulfonylfluoride). Specifically disclosed is a method for producing a compound (1) wherein a compound (2F) is fluorinated. The compound (2F) is obtained by reacting a com...
|
|
WO/2008/110278A2 |
The use of N2-phenylamidines of general formula (I) as herbicides is disclosed. In said general formula (I) R2, R3, R4, R5 and R6 are various groups and A is a bond or various single- or multi-atom bridge elements.
|
|
WO/2008/111473A1 |
Disclosed is a compound represented by the formula (1) below or a pharmaceutically acceptable salt thereof. [chemical formula 1] (1) (In the formula, the configuration of a carbon atom marked with an asterisk (*) is R; R1 represents a hy...
|
|
WO/2008/107677A2 |
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X is an oxygen or sulphur atom A is CH(R6)-, -O- or NR7 or when A is NR7, then R1 and NR7 can together form a ring such that R1 and R7 are (CH2)n...
|
|
WO/2008/105607A1 |
A novel heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-r...
|
|
WO/2008/101665A1 |
The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection.
|
|
WO/2008/102348A1 |
Novel Alpha-halo- and Alpha-alkyl-cyclopropylcarboxy compounds, and uses of these and related compounds in the treatment of a variety of neurological diseases and disorders, and particularly epilepsy, are provided.
|
|
WO/2008/102908A1 |
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by the general formula (1) below, or an agrochemically acceptable salt thereof. (In the formula, Q represents -N(R5)SO2R6, wherein ...
|
|
WO/2008/093674A1 |
Disclosed is a compound represented by the formula (I) below or a salt thereof. In the formula, ring A represents a benzene ring, a thiophene ring or a pyridine ring; Ra represents a hydrogen atom, a halogen atom, an alkyl group or an al...
|
|
WO/2008/084872A1 |
Disclosed is a hydrazone derivative represented by the formula [I] below or a pharmacologically acceptable salt thereof, which is useful as a glucokinase activator. (In the formula, ring A represents an aryl or a heteroaryl; T represents...
|
|
WO/2008/077507A1 |
The present invention relates to heteroaryl-substituted carboxamides of the formula (I) in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) syntha...
|
|
WO/2008/078674A1 |
Disclosed is a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, wherein a carbon atom having an asterisk has an R-configuration; R1 and R2 independently represent a hydrogen atom, a halogen atom, an ...
|
|
WO/2008/077138A1 |
Compounds of formula (I): and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of G...
|
|
WO/2008/075026A1 |
The present invention provides compounds of formula (I) (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein Ra, Rb, R1, R2, R3, R4, R5, R6 and R29 are as defined in the specification, processes ...
|
|
WO/2008/076754A2 |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
|
|
WO/2008/074132A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...
|
|
WO/2008/073958A2 |
The present invention is directed to substituted benzothiadiazinedioxide derivatives of formula (I) :or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containin...
|
|
WO/2008/073459A1 |
The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, ...
|
|
WO/2008/073956A2 |
The present invention is directed to cyclic sulfonamide derivatives of formula (I): or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their u...
|
|
WO/2008/071421A1 |
Nitroderivatives of carbonic anhydrase inhibitors having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration...
|
|
WO/2008/061781A1 |
The invention provides novel 1,2,4-thiadiazole derivatives useful for preventing or treating an α-synucleopathy such as Parkinson's disease, as well as pharmaceutical compositions including them as biologically active ingredients, and m...
|
|
WO/2008/059025A1 |
The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions asso...
|
